Type 2 Diabetes accounted for a 35.5% share of the global clinical trials within the Metabolic Disorders therapy area in 2021, registering a decrease of 3.4% when compared with the last ten-year average of 38.9% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Type 2 Diabetes
Industry sponsored trials held a 56.9% share of all the clinical trials for Type 2 Diabetes indication in 2021, registering an increase of 12.8% when compared with the ten-year average of 44.1%. Non-industry sponsored trials accounted for a 43.1% share in 2021, marking a decrease of 12.8% over the ten-year average of 55.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Type 2 Diabetes trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Type 2 Diabetes trials, accounting for a 74.7% share in 2021, when compared with the five-year average of 62.7% and ten-year average of 56.3%.
North America was at the second position with a 16.2% share in 2021, over the five-year average of 22.2% and ten-year average of 31.2%, followed by Europe with a 15.3% share in 2021, as against five-year and ten-year averages of 28.6% and 31.9% respectively.
Middle East and Africa stood fourth with a 7.9% share in 2021, compared with the five-year average of 7.9% and ten-year average of 10.1%, followed by South and Central America with a 3.2% share in 2021, over five-year and ten-year averages of 4.7% and 7.1% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Type 2 Diabetes trials, accounting for a 43.2% share in 2021, as against the five-year average of 32.5% and ten-year average of 20.9%.
The US held a 14.4% share in 2021, over the five-year average of 20.6% and ten-year average of 29.3%, followed by South Korea with a 10.0% share in 2021, compared with the five-year and ten-year averages of 9.0% and 10.6% respectively.
India held a 9.4% share in 2021, as against the five-year average of 11.0% and ten-year average of 11.1%.
Japan held a 7.4% share in 2021, over the five-year and ten-year averages of 8.3% and 12.0% respectively.
Top regions of non-industry sponsored Type 2 Diabetes trials
Asia-Pacific was the top region for non-industry sponsored Type 2 Diabetes trials, accounting for a 49.4% share in 2021 when compared with the five-year average of 55.1% and ten-year average of 56.2%.
Middle East and Africa was at the second position with a 19.5% share in 2021, over the five-year and ten-year averages of 18.6% and 14.7% respectively, followed by Europe with a 14.8% share in 2021, as against the five-year average of 15.0% and ten-year average of 16.0%.
North America stood at the fourth position with a 14.0% share in 2021, compared with the five-year average of 10.2% and ten-year average of 12.2%, followed by South and Central America with a 2.7% share in 2021, over the five-year and ten-year averages of 1.4% and 1.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Type 2 Diabetes trials, accounting for a 26.8% share in 2021, as against the five-year average of 17.0% and ten-year average of 13.3%.
Iran held a 16.0% share in 2021, over the five-year average of 14.0% and ten-year average of 11.5%, followed by US with an 11.3% share, compared with the five-year and ten-year averages of 7.8% and 9.5% respectively.
India held a 7.4% share in 2021, as against the five-year average of 11.4% and ten-year average of 8.0%.
Japan held a 5.1% share in 2021, over the five-year average of 14.7% and ten-year average of 24.6%.
Phase I trials lead industry sponsored clinical trials for Type 2 Diabetes in 2021
Phase I trials held a 62.7% share of industry sponsored clinical trials for Type 2 Diabetes in 2021, over the five-year average of 50.4% and ten-year average of 44.6%.
Phase III trials held a 15.1% share in 2021, as against the five-year average of 18.6% and ten-year average of 21.9%. Phase II trials held a 12.8% share in 2021, compared with the five-year and ten-year averages of 16.5% and 17.3% respectively.
Phase IV trials held a 9.4% share in 2021, over the five-year average of 14.4% and ten-year average of 16.2%.
Phase IV trials lead non-industry sponsored clinical trials for Type 2 Diabetes in 2021
Phase IV trials held a 36.8% share of non-industry sponsored clinical trials for Type 2 Diabetes in 2021, over the five-year average of 29.8% and ten-year average of 31.4%.
Phase II trials held a 29.7% share in 2021, as against the five-year average of 46.3% and ten-year average of 47.8%. Phase III trials held a 20.7% share, compared with the five-year and ten-year averages of 15.3% and 13.4% respectively.
Phase I trials held a 12.8% share in 2021, over the five-year average of 8.6% and ten-year average of 7.4%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
